Evaluation of EB01 Cream for the Treatment of Chronic Allergic Contact Dermatitis
NCT ID: NCT03680131
Last Updated: 2024-11-14
Study Results
Results pending
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
Recruitment Status
COMPLETED
Clinical Phase
PHASE2
Total Enrollment
211 participants
Study Classification
INTERVENTIONAL
Study Start Date
2019-10-15
Study Completion Date
2023-01-17
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
The purpose of this study is to evaluate the safety and efficacy of EB01 Cream (0.2%, 1.0%, 2.0%) applied twice per day (BID) for the treatment of moderate to severe chronic allergic contact dermatitis (ACD).
The purpose of the open label extension is to assess the long-term safety, tolerability, and efficacy of EB01 2.0% cream in subjects with moderate to severe chronic allergic contact dermatitis.
The purpose of the open label extension is to assess the long-term safety, tolerability, and efficacy of EB01 2.0% cream in subjects with moderate to severe chronic allergic contact dermatitis.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
A Study in Patients With Atopic Eczema to Test How Effective BI 655130 is and How Well it is Tolerated
NCT03822832
Dermatitis, Atopic
COMPLETED
PHASE2
Different Application Rates of Crisaborole Ointment 2% in Adults With Mild to Moderate Atopic Dermatitis
NCT03868098
Dermatitis, Atopic
COMPLETED
PHASE4
A Study to Determine the Safety, Tolerability and Efficacy of KP-413 in Subjects With Atopic Dermatitis(AD)
NCT00932074
Atopic Dermatitis
COMPLETED
PHASE1/PHASE2
Assessment of Skin Tolerance and Efficacy of a Cosmetic Product After 5 Days of Use on Subjects With Atopic Dermatitis
NCT05807113
Atopic Diathesis
Eczema-prone Skin
COMPLETED
NA
This Study Will Evaluate the Safety, Tolerability, and Efficacy of ANB032 in Subjects with Moderate to Severe Atopic Dermatitis (AD).
NCT05935085
Atopic Dermatitis Eczema
TERMINATED
PHASE2
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Allergic Contact Dermatitis
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
Allocation Method
RANDOMIZED
Intervention Model
PARALLEL
Primary Study Purpose
TREATMENT
Blinding Strategy
QUADRUPLE
Participants
Caregivers
Investigators
Outcome Assessors
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
EB01 Cream Placebo
EB01 Cream containing 0% EB01 w/w applied BID
Group Type
ACTIVE_COMPARATOR
EB01 Cream Placebo
Intervention Type
DRUG
Vehicle Cream containing 0% EB w/w applied BID
EB01 Cream 0.2%
EB01 Cream containing 0.2% EB01 w/w applied BID
Group Type
EXPERIMENTAL
EB01 Cream 0.2%
Intervention Type
DRUG
EB01 Cream containing 0.2% EB01 w/w applied BID
EB01 Cream 1.0%
EB01 Cream containing 1.0% EB01 w/w applied BID
Group Type
EXPERIMENTAL
EB01 Cream 1.0%
Intervention Type
DRUG
EB01 Cream containing 1.0% EB01 w/w applied BID
EB01 Cream 2.0%
EB01 Cream containing 2.0% EB01 w/w applied BID
Group Type
EXPERIMENTAL
EB01 Cream 2.0%
Intervention Type
DRUG
EB01 Cream containing 2.0% EB01 w/w applied BID
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
EB01 Cream Placebo
Vehicle Cream containing 0% EB w/w applied BID
Intervention Type
DRUG
EB01 Cream 0.2%
EB01 Cream containing 0.2% EB01 w/w applied BID
Intervention Type
DRUG
EB01 Cream 1.0%
EB01 Cream containing 1.0% EB01 w/w applied BID
Intervention Type
DRUG
EB01 Cream 2.0%
EB01 Cream containing 2.0% EB01 w/w applied BID
Intervention Type
DRUG
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
All subjects:
1. Men and women ≥ 18 years old, inclusive, at the time of consent.
2. For women of childbearing potential involved in any sexual intercourse that could lead to pregnancy: the subject must agree to use an effective contraceptive method from at least 4 weeks before Day 1 until at least 4 weeks after the last study product application. Effective contraceptive methods include hormonal contraceptives (combined oral contraceptive, patch, vaginal ring, injectable, or implant), intrauterine devices or intrauterine systems, vasectomized partner(s), tubal ligation, or a barrier method of contraception (male condom, female condom, cervical cap, diaphragm, contraceptive sponge) in conjunction with spermicide.
Note: Subjects must have been on a stable dose of hormonal contraceptives for at least 4 weeks before Day 1.
Note: The above list of contraceptive methods does not apply to subjects who are abstinent for at least 4 weeks before Day 1 and will continue to be abstinent from penile-vaginal intercourse throughout the study. The reliability of sexual abstinence needs to be evaluated in relation to the duration of the clinical trial and the preferred and usual lifestyle of the participant.
Note: A woman of nonchildbearing potential is as follows:
1. Woman who has had surgical sterilization (hysterectomy, bilateral oophorectomy, or bilateral salpingectomy);
2. Woman who has had a cessation of menses for at least 12 months without an alternative medical cause, and a follicle-stimulating hormone (FSH) test confirming nonchildbearing potential (refer to laboratory reference ranges for confirmatory levels).
3. For men involved in any sexual intercourse that could lead to pregnancy, subject must agree to use one of the effective contraceptive methods listed in Inclusion Criterion #2 from Day 1 until at least 4 weeks after the last study product application. If the female partner of a male subject use any of the hormonal contraceptive methods listed above, this contraceptive method must be used by the female partner from at least 4 weeks before Day 1 until at least 4 weeks after the last study product application.
4. Female of childbearing potential has had a negative pregnancy test at screening visit.
5. Subject is willing to participate and is capable of giving informed consent. Note: Consent must be obtained prior to any study-related procedures.
6. Subjects must be willing to comply with all study procedures and must be available for the duration of the study.
HV only:
1\. Subject is in good general health, according to the investigator's judgment based on medical history and physical examination/laboratory/ECG/vital signs assessments.
Subjects with allergic contact dermatitis only:
1. Subject has at least 3-month history of allergic contact dermatitis (information obtained from medical chart or subject's physician, or directly from the subject).
2. Subject has moderate to severe chronic allergic contact dermatitis at Day 1, defined by either one of the following:
* CDSI score ≥ 7
* CDSI score of severe (3) in ≥ 2 of the 5 assessed symptoms (Fissures, Scaling, Redness, Pruritus, Dryness)
3. Subject has allergic contact dermatitis covering between 0.5% to 10% of the total BSA at Day 1.
4. Subject has an ISGA ≥ 3 at Day 1.
5. The subject has had a positive patch test ("+", "++" or "+++" reaction) to an allergen that is suspected to be involved in the current allergic contact dermatitis in the past 5 years (obtain written documentation of patch test result if possible).
Alternatively, the Subject agrees to undergo patch testing during the study period (patch testing needs to be completed by Day 36). Guidelines for patch test interpretation are provided in Appendix 2. The measure of the degree of the reaction will be determined on the basis of the reading 2 and 3-4 days post application.
6. Subject agrees to only apply personal care products (i.e. makeup and eyeshadow) that do not contain their allergen(s) on lesions only after applying the IP.
7. Subject agrees not to apply any personal care products on allergic contact dermatitis lesions prior to site visits.
Subjects with allergic contact dermatitis in the Open Label Extension:
1\. Subject has completed the main study.
1. Men and women ≥ 18 years old, inclusive, at the time of consent.
2. For women of childbearing potential involved in any sexual intercourse that could lead to pregnancy: the subject must agree to use an effective contraceptive method from at least 4 weeks before Day 1 until at least 4 weeks after the last study product application. Effective contraceptive methods include hormonal contraceptives (combined oral contraceptive, patch, vaginal ring, injectable, or implant), intrauterine devices or intrauterine systems, vasectomized partner(s), tubal ligation, or a barrier method of contraception (male condom, female condom, cervical cap, diaphragm, contraceptive sponge) in conjunction with spermicide.
Note: Subjects must have been on a stable dose of hormonal contraceptives for at least 4 weeks before Day 1.
Note: The above list of contraceptive methods does not apply to subjects who are abstinent for at least 4 weeks before Day 1 and will continue to be abstinent from penile-vaginal intercourse throughout the study. The reliability of sexual abstinence needs to be evaluated in relation to the duration of the clinical trial and the preferred and usual lifestyle of the participant.
Note: A woman of nonchildbearing potential is as follows:
1. Woman who has had surgical sterilization (hysterectomy, bilateral oophorectomy, or bilateral salpingectomy);
2. Woman who has had a cessation of menses for at least 12 months without an alternative medical cause, and a follicle-stimulating hormone (FSH) test confirming nonchildbearing potential (refer to laboratory reference ranges for confirmatory levels).
3. For men involved in any sexual intercourse that could lead to pregnancy, subject must agree to use one of the effective contraceptive methods listed in Inclusion Criterion #2 from Day 1 until at least 4 weeks after the last study product application. If the female partner of a male subject use any of the hormonal contraceptive methods listed above, this contraceptive method must be used by the female partner from at least 4 weeks before Day 1 until at least 4 weeks after the last study product application.
4. Female of childbearing potential has had a negative pregnancy test at screening visit.
5. Subject is willing to participate and is capable of giving informed consent. Note: Consent must be obtained prior to any study-related procedures.
6. Subjects must be willing to comply with all study procedures and must be available for the duration of the study.
HV only:
1\. Subject is in good general health, according to the investigator's judgment based on medical history and physical examination/laboratory/ECG/vital signs assessments.
Subjects with allergic contact dermatitis only:
1. Subject has at least 3-month history of allergic contact dermatitis (information obtained from medical chart or subject's physician, or directly from the subject).
2. Subject has moderate to severe chronic allergic contact dermatitis at Day 1, defined by either one of the following:
* CDSI score ≥ 7
* CDSI score of severe (3) in ≥ 2 of the 5 assessed symptoms (Fissures, Scaling, Redness, Pruritus, Dryness)
3. Subject has allergic contact dermatitis covering between 0.5% to 10% of the total BSA at Day 1.
4. Subject has an ISGA ≥ 3 at Day 1.
5. The subject has had a positive patch test ("+", "++" or "+++" reaction) to an allergen that is suspected to be involved in the current allergic contact dermatitis in the past 5 years (obtain written documentation of patch test result if possible).
Alternatively, the Subject agrees to undergo patch testing during the study period (patch testing needs to be completed by Day 36). Guidelines for patch test interpretation are provided in Appendix 2. The measure of the degree of the reaction will be determined on the basis of the reading 2 and 3-4 days post application.
6. Subject agrees to only apply personal care products (i.e. makeup and eyeshadow) that do not contain their allergen(s) on lesions only after applying the IP.
7. Subject agrees not to apply any personal care products on allergic contact dermatitis lesions prior to site visits.
Subjects with allergic contact dermatitis in the Open Label Extension:
1\. Subject has completed the main study.
Exclusion Criteria
All subjects:
1. Subject is a female who is breastfeeding, pregnant, or who is planning to become pregnant during the study.
2. Current or recurrent disease, other than allergic contact dermatitis (applicable to subject with allergic contact dermatitis only), that could affect the action, absorption, or disposition of the study drug, or clinical or laboratory assessments.
3. Subject has a history of skin disease or presence of skin condition, other than allergic contact dermatitis (applicable to subject with allergic contact dermatitis only) that, in the opinion of the investigator, would interfere with the study assessments.
4. Subject is known to have immune deficiency or is immunocompromised.
5. Subject has a history of cancer or lymphoproliferative disease within 5 years prior to Day 1. Subjects with successfully treated non-metastatic cutaneous squamous cell or basal cell carcinoma and/or localized carcinoma in situ of the cervix are not to be excluded.
6. Subject had a major surgery within 8 weeks prior to Day 1 or has a major surgery planned during the study.
7. Subject has any clinically significant medical condition that would, in the opinion of the investigator, put the subject at undue risk or interfere with interpretation of study results.
8. Subject has a known history of chronic infectious disease (e.g., hepatitis B, hepatitis C, or infection with human immunodeficiency virus).
9. Subject has used systemic treatments (other than biologics) that could affect allergic contact dermatitis (applicable to subjects with allergic contact dermatitis only) or is known to cause cutaneous irritation or sensitization reactions less than 2 weeks prior to Day 1 (e.g., oral/injectable corticosteroids, retinoids, calcineurin inhibitors, methotrexate, cyclosporine, hydroxycarbamide \[hydroxyurea\], azathioprine) Note: Intranasal corticosteroids and inhaled corticosteroids for stable medical conditions are allowed. Eye drops containing corticosteroids are allowed.
10. Use of any prescription or over-the-counter (OTC) medication that, in the opinion of the Principal Investigator, could affect (improve or worsen) the allergic contact dermatitis condition or is known to cause cutaneous irritation or sensitization reactions.
11. Subject has received any marketed or investigational biological agent within 12 weeks or 5 half-lives (whichever is longer) prior to Day 1.
12. Subject is currently receiving a nonbiological investigational product or device or has received one within 2 weeks prior to Day 1.
13. Subject has received any UV-B phototherapy (including tanning beds) or excimer laser within 2 weeks prior to Day 1.
14. Subject had excessive sun exposure, is planning a trip to a sunny climate, or has used tanning booths within 2 weeks prior to Day 1 or is not willing to minimize natural and artificial sunlight exposure during the study. Use of sunscreen products and protective apparel are recommended when exposure cannot be avoided. If sunscreen is applied to ACD lesions, it should be applied after the IP.
15. Subject has a known hypersensitivity to EB01 or its excipients.
16. Subject has uncontrolled diabetes.
17. Subject has a known history of clinically significant drug or alcohol abuse in the last year prior to Day 1.
HV only:
1. Subject has history of recurrent chronic or presence of allergic contact dermatitis.
2. Subject has used any medicated topical product on the face within 2 weeks prior to Day 1.
Subjects with allergic contact dermatitis only:
1. Subjects with active atopic dermatitis lesions overlapping with allergic contact dermatitis lesions at Day 1.
2. Subject has clinically infected allergic contact dermatitis lesions (bacterial, viral, or fungal).
3. Subject has allergic contact dermatitis on lips or mucous membranes only.
4. Subject has used dupilumab within 12 weeks prior to Day 1.
5. Subject has used doxepin within 1 week prior to Day 1.
6. Subject has used hydroxyzine or diphenhydramine within 1 week prior to Day 1.
7. Subject has used topical products containing urea within 1 week prior to Day 1.
8. Subject has used systemic antibiotics within 2 weeks or topical antibiotics on lesions of allergic contact dermatitis within 1 week prior to Day 1.
9. Subject has used any topical medicated treatment for allergic contact dermatitis within 1 week prior to Day 1, including, but not limited to, topical corticosteroids, crisaborole and any other topical phosphodiesterase-4 inhibitor, calcineurin inhibitors, tars, bleach, antimicrobials and medical devices.
1. Subject is a female who is breastfeeding, pregnant, or who is planning to become pregnant during the study.
2. Current or recurrent disease, other than allergic contact dermatitis (applicable to subject with allergic contact dermatitis only), that could affect the action, absorption, or disposition of the study drug, or clinical or laboratory assessments.
3. Subject has a history of skin disease or presence of skin condition, other than allergic contact dermatitis (applicable to subject with allergic contact dermatitis only) that, in the opinion of the investigator, would interfere with the study assessments.
4. Subject is known to have immune deficiency or is immunocompromised.
5. Subject has a history of cancer or lymphoproliferative disease within 5 years prior to Day 1. Subjects with successfully treated non-metastatic cutaneous squamous cell or basal cell carcinoma and/or localized carcinoma in situ of the cervix are not to be excluded.
6. Subject had a major surgery within 8 weeks prior to Day 1 or has a major surgery planned during the study.
7. Subject has any clinically significant medical condition that would, in the opinion of the investigator, put the subject at undue risk or interfere with interpretation of study results.
8. Subject has a known history of chronic infectious disease (e.g., hepatitis B, hepatitis C, or infection with human immunodeficiency virus).
9. Subject has used systemic treatments (other than biologics) that could affect allergic contact dermatitis (applicable to subjects with allergic contact dermatitis only) or is known to cause cutaneous irritation or sensitization reactions less than 2 weeks prior to Day 1 (e.g., oral/injectable corticosteroids, retinoids, calcineurin inhibitors, methotrexate, cyclosporine, hydroxycarbamide \[hydroxyurea\], azathioprine) Note: Intranasal corticosteroids and inhaled corticosteroids for stable medical conditions are allowed. Eye drops containing corticosteroids are allowed.
10. Use of any prescription or over-the-counter (OTC) medication that, in the opinion of the Principal Investigator, could affect (improve or worsen) the allergic contact dermatitis condition or is known to cause cutaneous irritation or sensitization reactions.
11. Subject has received any marketed or investigational biological agent within 12 weeks or 5 half-lives (whichever is longer) prior to Day 1.
12. Subject is currently receiving a nonbiological investigational product or device or has received one within 2 weeks prior to Day 1.
13. Subject has received any UV-B phototherapy (including tanning beds) or excimer laser within 2 weeks prior to Day 1.
14. Subject had excessive sun exposure, is planning a trip to a sunny climate, or has used tanning booths within 2 weeks prior to Day 1 or is not willing to minimize natural and artificial sunlight exposure during the study. Use of sunscreen products and protective apparel are recommended when exposure cannot be avoided. If sunscreen is applied to ACD lesions, it should be applied after the IP.
15. Subject has a known hypersensitivity to EB01 or its excipients.
16. Subject has uncontrolled diabetes.
17. Subject has a known history of clinically significant drug or alcohol abuse in the last year prior to Day 1.
HV only:
1. Subject has history of recurrent chronic or presence of allergic contact dermatitis.
2. Subject has used any medicated topical product on the face within 2 weeks prior to Day 1.
Subjects with allergic contact dermatitis only:
1. Subjects with active atopic dermatitis lesions overlapping with allergic contact dermatitis lesions at Day 1.
2. Subject has clinically infected allergic contact dermatitis lesions (bacterial, viral, or fungal).
3. Subject has allergic contact dermatitis on lips or mucous membranes only.
4. Subject has used dupilumab within 12 weeks prior to Day 1.
5. Subject has used doxepin within 1 week prior to Day 1.
6. Subject has used hydroxyzine or diphenhydramine within 1 week prior to Day 1.
7. Subject has used topical products containing urea within 1 week prior to Day 1.
8. Subject has used systemic antibiotics within 2 weeks or topical antibiotics on lesions of allergic contact dermatitis within 1 week prior to Day 1.
9. Subject has used any topical medicated treatment for allergic contact dermatitis within 1 week prior to Day 1, including, but not limited to, topical corticosteroids, crisaborole and any other topical phosphodiesterase-4 inhibitor, calcineurin inhibitors, tars, bleach, antimicrobials and medical devices.
Minimum Eligible Age
18 Years
Eligible Sex
ALL
Accepts Healthy Volunteers
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
JSS Medical Research Inc.
INDUSTRY
Sponsor Role
collaborator
Edesa Biotech Inc.
INDUSTRY
Sponsor Role
lead
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Responsibility Role
SPONSOR
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Ark Clinical Research
Long Beach, California, United States
Site Status
Foxhall Dermatology
Washington D.C., District of Columbia, United States
Site Status
Gold Coast Dermatology
Delray Beach, Florida, United States
Site Status
Miami Dade Medical Research Institute, LLC
Miami, Florida, United States
Site Status
The Dermatology Centre of Indiana
Plainfield, Indiana, United States
Site Status
Forefront Dermatology
Louisville, Kentucky, United States
Site Status
The Dermatology Clinic
Baton Rouge, Louisiana, United States
Site Status
Oakland Hills Dermatology P.C.
Auburn Hills, Michigan, United States
Site Status
Associated Skin Care Specialists
Fridley, Minnesota, United States
Site Status
JUVA Skin & Laser Center
New York, New York, United States
Site Status
UNC Dermatology and Skin Cancer Center
Chapel Hill, North Carolina, United States
Site Status
Bexly Dermatology
Bexley, Ohio, United States
Site Status
Apex Clinical Research Center, LLC
Mayfield Heights, Ohio, United States
Site Status
West Virginia Research Institute
Morgantown, West Virginia, United States
Site Status
Lynderm Research Inc.
Markham, Ontario, Canada
Site Status
Countries
Review the countries where the study has at least one active or historical site.
United States
Canada
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
EB01-01-2018
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.
Validation of the Short-term Antimicrobial Action of Transplanted Bacteria
NCT01959113
COMPLETED
PHASE1
A Study to Learn How Well the Study Treatment Zabedosertib (BAY1834845) Works and How Safe it is Compared to Placebo in Adult Participants With Moderate-to-severe Atopic Dermatitis
NCT05656911
COMPLETED
PHASE2
Study to Evaluate the Efficacy, Safety and Pharmacokinetics of ASB17061 Capsules in Adult Subjects With Atopic Dermatitis
NCT01756898
COMPLETED
PHASE2
Efficacy and Tolerability of New Topical Formulations in Subjects With Atopic Dermatitis
NCT02732314
COMPLETED
PHASE4
Study of TER-101 Topical Ointment in Subjects With Atopic Dermatitis
NCT04753034
COMPLETED
PHASE2
A Single-ascending Dose (Part A) and Repeat-dose (Part B) Study to Investigate the Safety, Pharmacokinetics and Efficacy (Part B Only) of UCB1381 in Healthy Study Participants (Part A) and in Study Participants With Moderate to Severe Atopic Dermatitis (Part B)
NCT05277571
COMPLETED
PHASE1/PHASE2
Efficacy and Safety of AN2898 and AN2728 Topical Ointments to Treat Mild-to-Moderate Atopic Dermatitis
NCT01301508
COMPLETED
PHASE2
A Study to Evaluate the Anti-pruritic Effectiveness of ASN008 in Adults With Mild to Moderate Atopic Dermatitis
NCT05870865
COMPLETED
PHASE2
An Open-label, Single-arm Longitudinal Study With Dupilumab for Patients With Atopic Dermatitis
NCT04520308
UNKNOWN
PHASE4
Evaluation of the Kinetic Properties of an Autologous Microbiome Transplant in Adult Atopic Dermatitis Patients
NCT02144142
WITHDRAWN
PHASE2
A Study of Upadacitinib in Adult Participants With Moderate-to-Severe Atopic Dermatitis and Inadequate Response to Dupilumab
NCT06389136
RECRUITING
PHASE3
Safety, Tolerability and Efficacy of ZEP-3Na (0.1% or 1%) Compared to Placebo in Subjects With Mild to Moderate Atopic Dermatitis
NCT04307862
UNKNOWN
PHASE2
Dose Ranging Study to Assess Efficacy, Safety, Tolerability and Pharmacokinetics of PF-06700841 Topical Cream in Participants With Mild or Moderate Atopic Dermatitis
NCT03903822
COMPLETED
PHASE2
Efficacy and Safety of Different Concentrations of ZK245186 in Atopic Dermatitis (AD)
NCT01228513
COMPLETED
PHASE2
Safety and Efficacy Study of Q301 in Moderate to Severe Atopic Dermatitis Patients
NCT02426359
COMPLETED
PHASE2
Safety and Efficacy Study of Topically Applied DS107 Cream in Mild to Moderate Atopic Dermatitis Patients (AD)
NCT02925793
COMPLETED
PHASE2
Comparison of the Efficacy and Safety of Two Topical Creams for Pediatric Atopic Dermatitis
NCT00828412
COMPLETED
PHASE4
Efficacy, Safety, Tolerability, Pharmacokinetics and Pharmacodynamics Study of the Topical Formulation SB011 Applied to Lesional Skin in Patients With Atopic Eczema
NCT02079688
COMPLETED
PHASE2
Targeted Investigation of Microbiome Elimination
NCT05177328
TERMINATED
PHASE1
A Study of the Effects of Camoteskimab in Adults With Moderate to Severe Atopic Dermatitis
NCT06436183
COMPLETED
PHASE2
Efficacy, Safety, and Pharmacokinetic Profile of Etokimab (ANB020) in Adult Participants With Moderate-to-Severe Atopic Dermatitis
NCT03533751
COMPLETED
PHASE2
The Effects of Dupilumab on Allergic Contact Dermatitis
NCT03935971
ACTIVE_NOT_RECRUITING
PHASE4
Study to Investigate the Efficacy and Safety of Dupilumab Administered With Topical Corticosteroids (TCS) in Participants ≥6 to <12 Years With Severe Atopic Dermatitis (AD)
NCT03345914
COMPLETED
PHASE3
A Study Investigating the Effect of EDP1815 in the Treatment of Mild, Moderate and Severe Atopic Dermatitis
NCT05121480
COMPLETED
PHASE2